Central nervous system pharmacokinetics of high-dose cytosine arabinoside

Jose A. Lopez, Edgard Nassif, Paula Vannicola, John G. Krikorian, Ram P. Agarwal

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.l ug/ml) was about 7% of the plasma concentration (30 ug/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalJournal of Neuro-Oncology
Volume3
Issue number2
DOIs
StatePublished - Jun 1 1985
Externally publishedYes

Fingerprint

Cytarabine
Cerebrospinal Fluid
Central Nervous System
Pharmacokinetics
Intravenous Infusions
Half-Life
Lymphoma
Appointments and Schedules
Leukemia
High Pressure Liquid Chromatography
Therapeutics
Neoplasms

Keywords

  • CNS pharmacolocy of high dose Ara-C

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Lopez, J. A., Nassif, E., Vannicola, P., Krikorian, J. G., & Agarwal, R. P. (1985). Central nervous system pharmacokinetics of high-dose cytosine arabinoside. Journal of Neuro-Oncology, 3(2), 119-124. https://doi.org/10.1007/BF02228887

Central nervous system pharmacokinetics of high-dose cytosine arabinoside. / Lopez, Jose A.; Nassif, Edgard; Vannicola, Paula; Krikorian, John G.; Agarwal, Ram P.

In: Journal of Neuro-Oncology, Vol. 3, No. 2, 01.06.1985, p. 119-124.

Research output: Contribution to journalArticle

Lopez, JA, Nassif, E, Vannicola, P, Krikorian, JG & Agarwal, RP 1985, 'Central nervous system pharmacokinetics of high-dose cytosine arabinoside', Journal of Neuro-Oncology, vol. 3, no. 2, pp. 119-124. https://doi.org/10.1007/BF02228887
Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. Journal of Neuro-Oncology. 1985 Jun 1;3(2):119-124. https://doi.org/10.1007/BF02228887
Lopez, Jose A. ; Nassif, Edgard ; Vannicola, Paula ; Krikorian, John G. ; Agarwal, Ram P. / Central nervous system pharmacokinetics of high-dose cytosine arabinoside. In: Journal of Neuro-Oncology. 1985 ; Vol. 3, No. 2. pp. 119-124.
@article{f4e400250d50472ab2a3e43c90b55fd0,
title = "Central nervous system pharmacokinetics of high-dose cytosine arabinoside",
abstract = "The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.l ug/ml) was about 7{\%} of the plasma concentration (30 ug/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.",
keywords = "CNS pharmacolocy of high dose Ara-C",
author = "Lopez, {Jose A.} and Edgard Nassif and Paula Vannicola and Krikorian, {John G.} and Agarwal, {Ram P.}",
year = "1985",
month = "6",
day = "1",
doi = "10.1007/BF02228887",
language = "English",
volume = "3",
pages = "119--124",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Central nervous system pharmacokinetics of high-dose cytosine arabinoside

AU - Lopez, Jose A.

AU - Nassif, Edgard

AU - Vannicola, Paula

AU - Krikorian, John G.

AU - Agarwal, Ram P.

PY - 1985/6/1

Y1 - 1985/6/1

N2 - The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.l ug/ml) was about 7% of the plasma concentration (30 ug/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.

AB - The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.l ug/ml) was about 7% of the plasma concentration (30 ug/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.

KW - CNS pharmacolocy of high dose Ara-C

UR - http://www.scopus.com/inward/record.url?scp=0022263792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022263792&partnerID=8YFLogxK

U2 - 10.1007/BF02228887

DO - 10.1007/BF02228887

M3 - Article

C2 - 4031970

AN - SCOPUS:0022263792

VL - 3

SP - 119

EP - 124

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -